Gehrke, Nadine; Straub, Beate K.; Waisman, Ari et al.
IL-1 SIGNALING PROMOTES HEPATIC INSULIN RESISTANCE AND MITOCHONDRIAL INJURY IN NAFLD INVOLVING PGC-1alphaHEPATOLOGY. Bd. 70. 2019 S. 1304A-1305A
Costes, L. M. M.; Lindenbergh-Kortleve, D. J.; van Berkel, L. A. et al.
IL-10 signaling prevents gluten-dependent intraepithelial CD4(+) cytotoxic T lymphocyte infiltration and epithelial damage in the small intestineMUCOSAL IMMUNOLOGY. Bd. 12. H. 2. 2019 S. 479-490
Regen, T.; Isaac, S.; Amorim, A. De Oliveira et al.
IL-17 controls CNS autoimmunity through the intestinal microbiomeMULTIPLE SCLEROSIS JOURNAL. Bd. 25. 2019 S. 920-920
Lueckel, Christina; Picard, Felix; Raifer, Hartmann et al.
IL-17(+) CD8(+) T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosisNATURE COMMUNICATIONS. Bd. 10. 2019
Wada, Yukihiro; Gonzalez-Sanchez, Hilda M.; Weinmann-Menke, Julia et al.
IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Fas(lpr) MiceJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. Bd. 30. H. 2. 2019 S. 244-259
Kraemer, Julia; Brueck, Wolfgang; Zipp, Frauke et al.
Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniquesPROGRESS IN NEUROBIOLOGY. Bd. 182. 2019
Futterer, Jurgen J.; Surcel, Cristian; van den Bergh, Roderick et al.
Imaging modalities in synchronous oligometastatic prostate cancerWORLD JOURNAL OF UROLOGY. Bd. 37. H. 12. 2019 S. 2573-2583
Daldrup-Link, H. E.; Theruvath, A. J.; Nejadnik, H. et al.
Imaging Therapeutic Cell Transplants in Patients With Avascular OsteonecrosisINVESTIGATIVE RADIOLOGY. Bd. 54. H. 12. 2019 S. 806-806
Nestle, U.; Schimek-Jasch, T.; Kremp, S. et al.
Imaging-Guided Target Volume Reduction in Radiotherapy of Lung Cancer: The Prospective Randomized Multinational PET-Plan TrialJOURNAL OF THORACIC ONCOLOGY. Bd. 14. H. 10. 2019 S. S238-S238
Cheng, A-L.; Qin, S.; Ikeda, M. et al.
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)ANNALS OF ONCOLOGY. Bd. 30. 2019